George Clinical is proud to have been one of only four finalists for the 2024 Citeline Clinical Research Team of the Year. This award recognizes the clinical research team who has made significant contributions in advancing a new therapy through one or more clinical phases. Criteria included a high-performing team successful in reaching its goals, adopting effective working practices, achieving major milestones within expected timelines and contributing to the advancement of new therapies.
George Clinical was selected based on our involvement in an important Phase II global IgA nephropathy (IgAN) study. In addition to handling all Asia-Pacific (APAC) operations in 10 countries, we were also asked to include scientific leadership services.
Despite occurring at the height of the COVID shutdown, APAC sites recruited >60% of all global recruits with no loss to follow up, and >60% of site selection visits were completed within only eight weeks of project award—much earlier than US or EU sites. The personal relationships and influence of our Scientific Leaders were impactful in communicating scientific goals to investigators and lending cohesion across all sites. Our 10 National Leaders on the ground in the various countries aided in rapid and optimum recruitment.
The high APAC recruitment also meant that the racial and demographic composition of the study was consistent with the known distribution of IgAN—reflecting the higher prevalence and more rapid progression of IgAN in Asian populations.
The results of the study were extremely positive and in the follow-up Phase III study George Clinical was contracted for global Scientific Leadership and operations in 12 APAC countries.
George Clinical recently received the award for Clinical Research Team of the Year at the 7th Annual Citeline Awards held in Boston, MA. As a 2023 winner, the George Clinical team won recognition for a multi-site program in the Asia Pacific region that recruited more than 3,000 patients across 14 sites in just seven weeks.
The award recognizes the clinical research team who has made significant contributions advancing a new therapy through one or more clinical phases. The judges look to reward the high performing team that has been most successful in reaching its goals, adopted effective work practices, creative solutions and achieved major milestones within expected timelines and contributed to the advancement of new therapies.
The Citeline judges’ comments noted: “Speed, communication and a strong customer focus among this team enabled remarkable progress… Selection of low to middle income countries promoted accessibility of this convenient delivery technology for a diverse population. The team engaged the entire investigator site team by promoting the scientific value of the study, and through effective coordination of key activities across all study stakeholders.”
The Citeline Awards, organized by Pharma Intelligence, bring together hundreds of renowned leaders in biopharmaceuticals, CRO and diagnostics, to honor the greatest innovations in clinical R&D. The awards toast the inspirational work and tireless commitment shown by the brightest minds in the industry.
Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in kidney research, oncology and neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has its roots. It operates on the central tenet that its success depends on customer satisfaction, so it provides a human touch to its projects.
Azza Fazar, Frost & Sullivan best practices research analyst, observed, “George Clinical combines its connections with AROs and scientific expertise to find suitable sites and investigator networks, a unique competitive differentiator. The company facilitates faster patient-centric recruitment for its clients by bringing the best of both worlds.”
Based on its recent analysis of the Asia-Pacific clinical contract research organization (CRO) industry, Frost & Sullivan recognizes George Clinical with the 2021 Asia-Pacific Competitive Strategy Leadership Award. As a leading APAC Clinical CRO company, George Clinical formulates solutions with innovation and scientific leadership to produce high-quality outcomes and maintain growth in the evolving CRO market. The company uses Protocol First, 4G Clinical, and clinical information technology solution vendors to compete effectively with other CROs without significant investments. These vendors enable efficient and proactive clinical trial execution.
With its strong focus on scientific leadership and strategic excellence, George Clinical earns Frost & Sullivan’s 2021 APAC Competitive Strategy Leadership Award in the clinical CRO market. Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to execute a strategy successfully that results in stronger market share, competitive brand positioning, and customer satisfaction. Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.
Citeline has named George Clinical as a finalist for their 2021 Clinical Research Team of the Year. Citeline, a comprehensive global R&D intelligence firm provides insights into the global clinical trial landscape and the development of clinical trial programs, selected the DARE-19 team of George Clinical based on their compelling international accomplishments during the height of the COVID-19 pandemic.
This award recognizes the clinical research teams who have made significant contributions in advancing a new therapy through one or more clinical phases. “The judges look to reward the high-performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies,” according to Pharma Intelligence.
Mikhail N. Kosiborod, MD, a member of George Clinical’s scientific leadership was the principal investigator of DARE-19. The study was an international Phase III trial in 1,250 patients evaluating the efficacy and safety of Farxiga in addition to background local standard of care therapy in adults who are hospitalized with COVID-19 at the time of trial enrollment. The trial was conducted in collaboration with Saint Luke’s Mid America Heart Institute, the global sponsor, and George Clinical, a global contract research organization.
George Clinical is also pleased to have been recognized by Scrip Awards from Informa Pharma Intelligence as a 2021 Finalist for Best Contract Research Organization—Full-Service Providers. The awards highlight the best of the best in the field noting “these are the unsung heroes who have taken it upon themselves to make a difference, to push for the next breakthrough, to find a cure, to end suffering, to extend a life.” The Citeline Awards judging panel is comprised of independent, international senior industry experts each of whom is chosen for their “knowledge, objectivity and credibility.
